GDS Wealth Management Grows Position in Axon Enterprise, Inc $AXON

GDS Wealth Management boosted its position in Axon Enterprise, Inc (NASDAQ:AXON) by 8.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,845 shares of the biotechnology company’s stock after acquiring an additional 1,357 shares during the period. GDS Wealth Management’s holdings in Axon Enterprise were worth $12,089,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Mn Services Vermogensbeheer B.V. increased its position in shares of Axon Enterprise by 1.1% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 27,500 shares of the biotechnology company’s stock valued at $19,735,000 after buying an additional 300 shares during the period. Resona Asset Management Co. Ltd. grew its holdings in shares of Axon Enterprise by 11.8% during the 3rd quarter. Resona Asset Management Co. Ltd. now owns 103,852 shares of the biotechnology company’s stock worth $74,477,000 after acquiring an additional 10,999 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its position in shares of Axon Enterprise by 1.2% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 31,651 shares of the biotechnology company’s stock worth $22,714,000 after acquiring an additional 361 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in shares of Axon Enterprise by 18.2% in the 3rd quarter. UniSuper Management Pty Ltd now owns 6,831 shares of the biotechnology company’s stock valued at $4,902,000 after purchasing an additional 1,053 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after purchasing an additional 330,213 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Insider Activity at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 1,134 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $600.00, for a total value of $680,400.00. Following the sale, the chief accounting officer owned 13,740 shares in the company, valued at approximately $8,244,000. This trade represents a 7.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey C. Kunins sold 1,797 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $539.23, for a total transaction of $968,996.31. Following the completion of the sale, the insider directly owned 83,485 shares of the company’s stock, valued at approximately $45,017,616.55. This trade represents a 2.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 60,540 shares of company stock valued at $34,684,738 over the last quarter. 4.40% of the stock is owned by company insiders.

Axon Enterprise Stock Up 1.0%

AXON stock opened at $613.14 on Friday. The stock has a market capitalization of $48.38 billion, a P/E ratio of 194.03, a P/E/G ratio of 19.30 and a beta of 1.41. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. Axon Enterprise, Inc has a 1-year low of $469.24 and a 1-year high of $885.91. The business has a fifty day moving average price of $576.17 and a 200-day moving average price of $676.14.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The business had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. During the same quarter in the previous year, the business posted $1.45 earnings per share. Axon Enterprise’s quarterly revenue was up 30.6% compared to the same quarter last year. Equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Piper Sandler cut their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Barclays lowered their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Finally, Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target on the stock in a research note on Tuesday, January 6th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and an average target price of $805.71.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.